UniProtKB/SwissProt variant VAR

Variant information

Variant position:

104

The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:

Disease [Disclaimer]

The variants are classified into three categories: Disease, Polymorphism and Unclassified.

Disease: Variants implicated in disease according to literature reports.
Polymorphism: Variants not reported to be implicated in disease.
Unclassified: Variants with uncertain implication in disease according to literature reports. Evidence against or in favor of a pathogenic role is limited and/or conflicting.

Residue change:

From Lysine (K) to Glutamine (Q) at position 104 (K104Q, p.Lys104Gln).

Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:

Change from large size and basic (K) to medium size and polar (Q)

The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:

1

The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:

Lowest score: -4 (low probability of substitution).
Highest score: 11 (high probability of substitution).

More information can be found on the following page

Involvement in disease:

Norrie disease (ND) [MIM:310600]: Recessive disorder characterized by very early childhood blindness due to degenerative and proliferative changes of the neuroretina. Approximately 50% of patients show some form of progressive mental disorder, often with psychotic features, and about one-third of patients develop sensorineural deafness in the second decade. In addition, some patients have more complex phenotypes, including growth failure and seizure. {ECO:0000269|PubMed:10484772, ECO:0000269|PubMed:10544980, ECO:0000269|PubMed:11337749, ECO:0000269|PubMed:1303264, ECO:0000269|PubMed:1307245, ECO:0000269|PubMed:14635119, ECO:0000269|PubMed:15609522, ECO:0000269|PubMed:15776010, ECO:0000269|PubMed:16970763, ECO:0000269|PubMed:17128466, ECO:0000269|PubMed:17296899, ECO:0000269|PubMed:17325173, ECO:0000269|PubMed:17334993, ECO:0000269|PubMed:20340138, ECO:0000269|PubMed:7627181, ECO:0000269|PubMed:7662640, ECO:0000269|PubMed:7795608, ECO:0000269|PubMed:7993212, ECO:0000269|PubMed:8069314, ECO:0000269|PubMed:8268931, ECO:0000269|PubMed:8281159, ECO:0000269|PubMed:8589700, ECO:0000269|PubMed:8741107, ECO:0000269|PubMed:8807344, ECO:0000269|PubMed:8990009, ECO:0000269|PubMed:9143918, ECO:0000269|PubMed:9382152, ECO:0000269|PubMed:9407136}. Note=The disease is caused by mutations affecting the gene represented in this entry.

The name and a short description of the disease associated with the variant. For more information about the disease, the user can refer to OMIM, following the link provided after the disease acronym.

Variant description:

In ND.

Any additional useful information about the variant.

Sequence information

Variant position:

104

The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:

133

The length of the canonical sequence.

Location on the sequence:

VLKQPFRSSCHCCRPQTSKL K ALRLRCSGGMRLTATYRYIL

The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Residue conservation:

The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         VLKQPFRSSCHCCRPQTSKLKALRLRCSGGMRLTATYRYIL

Mouse                         VLKQPFRSSCHCCRPQTSKLKALRLRCSGGMRLTATYRYIL

Bovine                        VLKQPFRSSCHCCRPQTSKLKALRLRCSGGMRLTATYRYIL

Sequence annotation in neighborhood:

The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:

Type: the type of sequence feature.
Positions: endpoints of the sequence feature.
Description: contains additional information about the feature.

Type	Positions	Description
Chain	25 – 133	Norrin
Domain	39 – 132	CTCK
Disulfide bond	55 – 110
Disulfide bond	65 – 126
Disulfide bond	69 – 128
Disulfide bond	93 – 93	Interchain (with C-95)
Disulfide bond	95 – 95	Interchain (with C-93)
Mutagenesis	95 – 95	C -> A. Impairs oligomerization.
Beta strand	94 – 110

Literature citations

Missense mutations in the NDP gene in patients with a less severe course of Norrie disease.
Meindl A.; Lorenz B.; Achatz H.; Hellebrand H.; Schmitz-Valckenberg P.; Meitinger T.;
Hum. Mol. Genet. 4:489-490(1995)
Cited for: VARIANTS ND GLN-104; TRP-121 AND GLN-121;

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot Q00604: Variant p.Lys104Gln